Bank of New York Mellon Corp Lowers Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Bank of New York Mellon Corp lowered its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 5.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 958,684 shares of the medical research company’s stock after selling 55,948 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.73% of Natera worth $151,760,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Principal Securities Inc. boosted its position in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Gladstone Institutional Advisory LLC boosted its position in Natera by 1.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock worth $574,000 after purchasing an additional 61 shares in the last quarter. Silver Oak Securities Incorporated boosted its position in Natera by 3.1% during the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock worth $470,000 after purchasing an additional 89 shares in the last quarter. Covestor Ltd boosted its position in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares in the last quarter. Finally, Blue Trust Inc. boosted its position in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Trading Down 0.7 %

NTRA opened at $155.59 on Friday. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00. The business has a fifty day simple moving average of $167.56 and a 200-day simple moving average of $146.67. The firm has a market cap of $20.54 billion, a P/E ratio of -88.40 and a beta of 1.66. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of research analyst reports. Piper Sandler increased their target price on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Barclays initiated coverage on Natera in a report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 target price for the company. Morgan Stanley increased their target price on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $180.00 target price on shares of Natera in a report on Wednesday. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average price target of $172.69.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 78,553 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the transaction, the chief executive officer now owns 267,629 shares in the company, valued at $44,150,756.13. The trade was a 22.69 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Solomon Moshkevich sold 4,858 shares of Natera stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $166.59, for a total value of $809,294.22. Following the completion of the sale, the insider now directly owns 114,912 shares in the company, valued at $19,143,190.08. This represents a 4.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 295,772 shares of company stock worth $49,741,699 over the last ninety days. Corporate insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.